103 results on '"Lo Re III, Vincent"'
Search Results
2. Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar.
- Author
-
Marquez, Lara K, Chaillon, Antoine, Soe, Kyi Pyar, Johnson, Derek C, Zosso, Jean-Marc, Incerti, Andrea, Loarec, Anne, Nguyen, Aude, Walker, Josephine G, Mafirakureva, Nyashadzaishe, Lo Re Iii, Vincent, Wynn, Adriane, McIntosh, Craig, Kiene, Susan M, Brodine, Stephanie, Garfein, Richard S, Vickerman, Peter, and Martin, Natasha K
- Subjects
HIV ,health economics ,viral hepatitis - Abstract
IntroductionOver half of those hepatitis C virus (HCV)/HIV coinfected live in low-income and middle-income countries, and many remain undiagnosed or untreated. In 2016, Médecins Sans Frontières (MSF) established a direct-acting antiviral (DAA) treatment programme for people HCV/HIV coinfected in Myanmar. The purpose of our study was to evaluate the real-world cost and cost-effectiveness of this programme, and potential cost-effectiveness if implemented by the Ministry of Health (MoH).MethodsCosts (patient-level microcosting) and treatment outcomes were collected from the MSF prospective cohort study in Dawei, Myanmar. A Markov model was used to assess cost-effectiveness of the programme compared with no HCV treatment from a health provider perspective. Estimated lifetime and healthcare costs (in 2017 US$) and health outcomes (in disability-adjusted life-years (DALYs)) were simulated to calculate the incremental cost-effectiveness ratio (ICER), compared with a willingness-to-pay threshold of per capita Gross Domestic Product in Myanmar ($1250). We evaluated cost-effectiveness with updated quality-assured generic DAA prices and potential cost-effectiveness of a proposed simplified treatment protocol with updated DAA prices if implemented by the MoH.ResultsFrom November 2016 to October 2017, 122 with HIV/HCV-coinfected patients were treated with DAAs (46% with cirrhosis), 96% (n=117) achieved sustained virological response. Mean treatment costs were $1229 (without cirrhosis) and $1971 (with cirrhosis), with DAA drugs being the largest contributor to cost. Compared with no treatment, the program was cost-effective (ICER $634/DALY averted); more so with updated prices for quality-assured generic DAAs (ICER $488/DALY averted). A simplified treatment protocol delivered by the MoH could be cost-effective if associated with similar outcomes (ICER $316/DALY averted).ConclusionsUsing MSF programme data, the DAA treatment programme for HCV among HIV-coinfected individuals is cost-effective in Myanmar, and even more so with updated DAA prices. A simplified treatment protocol could enhance cost-effectiveness if further rollout demonstrates it is not associated with worse treatment outcomes.
- Published
- 2021
3. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data.
- Author
-
Torgersen, Jessie, Mezochow, Alyssa K., Newcomb, Craig W., Carbonari, Dena M., Hennessy, Sean, Rentsch, Christopher T., Park, Lesley S., Tate, Janet P., Bräu, Norbert, Bhattacharya, Debika, Lim, Joseph K., Mezzacappa, Catherine, Njei, Basile, Roy, Jason A., Taddei, Tamar H., Justice, Amy C., and Lo Re III, Vincent
- Published
- 2024
- Full Text
- View/download PDF
4. The obstacle is the way: Finding a path to hepatitis C elimination.
- Author
-
Lo Re III, Vincent, Price, Jennifer C., Schmitt, Steven, Terrault, Norah, Bhattacharya, Debika, and Aronsohn, Andrew
- Published
- 2024
- Full Text
- View/download PDF
5. Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States
- Author
-
Lo Re III, Vincent, primary, Cocoros, Noelle, additional, Hubbard, Rebecca, additional, Dutcher, Sarah, additional, Newcomb, Craig, additional, Connolly, John, additional, Perez-Vilar, Silvia, additional, Carbonari, Dena, additional, Kempner, Maria, additional, Hernández-Muñoz, José, additional, Petrone, Andrew, additional, Pishko, Allyson, additional, Rogers Driscoll, Meighan, additional, Brash, James, additional, Burnett, Sean, additional, Cohet, Catherine, additional, Dahl, Matthew, additional, DeFor, Terese, additional, Delmestri, Antonella, additional, Djibo, Djeneba, additional, Duarte-Salles, Talita, additional, Harrington, Laura, additional, Kampman, Melissa, additional, Kuntz, Jennifer, additional, Kurz, Xavier, additional, Mercadé-Besora, Núria, additional, Pawloski, Pamala, additional, Rijnbeek, Peter, additional, Seager, Sarah, additional, Steiner, Claudia, additional, Verhamme, Katia, additional, Wu, Fangyun, additional, Zhou, Yunping, additional, Burn, Edward, additional, Paterson, J, additional, and Prieto-Alhambra, Daniel, additional
- Published
- 2024
- Full Text
- View/download PDF
6. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection
- Author
-
van Boemmel-Wegmann, Sascha, Lo Re, III, Vincent, and Park, Haesuk
- Published
- 2020
- Full Text
- View/download PDF
7. Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection
- Author
-
Ferrante, Nicole D. and Lo Re, III, Vincent
- Published
- 2020
- Full Text
- View/download PDF
8. W31 - The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis
- Author
-
Haque, Lamia, Fiellin, David, Bryant, Kendall, Jennifer Edelman, E., Justice, Amy, Lim, Joseph, Lo Re III, Vincent, Marshall, Brandon, Taddei, Tamar, Tate, Janet, Tetrault, Jeanette, Williams, Emily, and McGinnis, Kathleen
- Published
- 2024
- Full Text
- View/download PDF
9. Strategies for the Elimination of Hepatitis C Virus Infection as a Public Health Threat in the United States
- Author
-
Gowda, Charitha and Lo Re, III, Vincent
- Published
- 2018
- Full Text
- View/download PDF
10. Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people
- Author
-
Torgersen, Jessie, So-Armah, Kaku, Freiberg, Matthew S., Goetz, Matthew B., Budoff, Matthew J., Lim, Joseph K., Taddei, Tamar, Butt, Adeel A., Rodriguez-Barradas, Maria C., Justice, Amy C., Kostman, Jay R., and Lo Re, III, Vincent
- Published
- 2019
- Full Text
- View/download PDF
11. Epigenome-wide association study of biomarkers of liver function identifies albumin-associated DNA methylation sites among male veterans with HIV
- Author
-
Titanji, Boghuma K., primary, Lee, Mitch, additional, Wang, Zeyuan, additional, Chen, Junyu, additional, Hui, Qin, additional, Lo Re III, Vincent, additional, So-Armah, Kaku, additional, Justice, Amy C., additional, Xu, Ke, additional, Freiberg, Matthew, additional, Gwinn, Marta, additional, Marconi, Vincent C., additional, and Sun, Yan V., additional
- Published
- 2022
- Full Text
- View/download PDF
12. Evaluation of methods to estimate missing days’ supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)
- Author
-
Lum, Kirsten J., Newcomb, Craig W., Roy, Jason A., Carbonari, Dena M., Saine, M. Elle, Cardillo, Serena, Bhullar, Harshvinder, Gallagher, Arlene M., and Lo Re, III, Vincent
- Published
- 2017
- Full Text
- View/download PDF
13. Altered adipose tissue macrophage populations in people with HIV on integrase inhibitor-containing antiretroviral therapy.
- Author
-
Vakili, Sarah, Paneru, Bam, Guerrier, Cleandre M., Miller, Jessica, Baumrin, Emily, Forrestel, Amy, Lynn, Kenneth, Frank, Ian, Lo Re III, Vincent, Collman, Ronald G., Hill, David A., and Lo Re, Vincent 3rd
- Published
- 2022
- Full Text
- View/download PDF
14. Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients.
- Author
-
Lo Re III, Vincent, Dutcher, Sarah K., Connolly, John G., Perez-Vilar, Silvia, Carbonari, Dena M., DeFor, Terese A., Djibo, Djeneba Audrey, Harrington, Laura B., Hou, Laura, Hennessy, Sean, Hubbard, Rebecca A., Kempner, Maria E., Kuntz, Jennifer L., McMahill-Walraven, Cheryl N., Mosley, Jolene, Pawloski, Pamala A., Petrone, Andrew B., Pishko, Allyson M., Driscoll, Meighan Rogers, and Steiner, Claudia A.
- Abstract
Key Points: Question: Is the 90-day incidence of arterial thromboembolism and venous thromboembolism higher in patients hospitalized with COVID-19 vs in patients hospitalized with influenza? Findings: In this retrospective cohort study that included 93 906 patients, hospitalization with COVID-19 before vaccine availability and during vaccine availability was significantly associated with higher 90-day risk of venous thromboembolism (adjusted hazard ratios, 1.60 and 1.89, respectively) vs hospitalization with influenza in 2018-2019, but there was no significant difference in the risk of arterial thromboembolism among those hospitalized with COVID-19 during either period (adjusted hazard ratios, 1.04 and 1.07) vs those hospitalized with influenza. Meaning: Hospitalization with COVID-19 both before and during vaccine availability was significantly associated with a higher risk of venous thromboembolism, but not arterial thromboembolism, vs hospitalization with influenza in 2018-2019. Importance: The incidence of arterial thromboembolism and venous thromboembolism in persons with COVID-19 remains unclear. Objective: To measure the 90-day risk of arterial thromboembolism and venous thromboembolism in patients hospitalized with COVID-19 before or during COVID-19 vaccine availability vs patients hospitalized with influenza. Design, Setting, and Participants: Retrospective cohort study of 41 443 patients hospitalized with COVID-19 before vaccine availability (April-November 2020), 44 194 patients hospitalized with COVID-19 during vaccine availability (December 2020-May 2021), and 8269 patients hospitalized with influenza (October 2018-April 2019) in the US Food and Drug Administration Sentinel System (data from 2 national health insurers and 4 regional integrated health systems). Exposures: COVID-19 or influenza (identified by hospital diagnosis or nucleic acid test). Main Outcomes and Measures: Hospital diagnosis of arterial thromboembolism (acute myocardial infarction or ischemic stroke) and venous thromboembolism (deep vein thrombosis or pulmonary embolism) within 90 days. Outcomes were ascertained through July 2019 for patients with influenza and through August 2021 for patients with COVID-19. Propensity scores with fine stratification were developed to account for differences between the influenza and COVID-19 cohorts. Weighted Cox regression was used to estimate the adjusted hazard ratios (HRs) for outcomes during each COVID-19 vaccine availability period vs the influenza period. Results: A total of 85 637 patients with COVID-19 (mean age, 72 [SD, 13.0] years; 50.5% were male) and 8269 with influenza (mean age, 72 [SD, 13.3] years; 45.0% were male) were included. The 90-day absolute risk of arterial thromboembolism was 14.4% (95% CI, 13.6%-15.2%) in patients with influenza vs 15.8% (95% CI, 15.5%-16.2%) in patients with COVID-19 before vaccine availability (risk difference, 1.4% [95% CI, 1.0%-2.3%]) and 16.3% (95% CI, 16.0%-16.6%) in patients with COVID-19 during vaccine availability (risk difference, 1.9% [95% CI, 1.1%-2.7%]). Compared with patients with influenza, the risk of arterial thromboembolism was not significantly higher among patients with COVID-19 before vaccine availability (adjusted HR, 1.04 [95% CI, 0.97-1.11]) or during vaccine availability (adjusted HR, 1.07 [95% CI, 1.00-1.14]). The 90-day absolute risk of venous thromboembolism was 5.3% (95% CI, 4.9%-5.8%) in patients with influenza vs 9.5% (95% CI, 9.2%-9.7%) in patients with COVID-19 before vaccine availability (risk difference, 4.1% [95% CI, 3.6%-4.7%]) and 10.9% (95% CI, 10.6%-11.1%) in patients with COVID-19 during vaccine availability (risk difference, 5.5% [95% CI, 5.0%-6.1%]). Compared with patients with influenza, the risk of venous thromboembolism was significantly higher among patients with COVID-19 before vaccine availability (adjusted HR, 1.60 [95% CI, 1.43-1.79]) and during vaccine availability (adjusted HR, 1.89 [95% CI, 1.68-2.12]). Conclusions and Relevance: Based on data from a US public health surveillance system, hospitalization with COVID-19 before and during vaccine availability, vs hospitalization with influenza in 2018-2019, was significantly associated with a higher risk of venous thromboembolism within 90 days, but there was no significant difference in the risk of arterial thromboembolism within 90 days. This cohort study uses data from the US Food and Drug Administration Sentinel System to measure the 90-day risk of arterial thromboembolism and venous thromboembolism among patients hospitalized with COVID-19 before and during COVID-19 vaccine availability vs patients hospitalized with influenza. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Adherence to Hepatitis C Virus Therapy in HIV/Hepatitis C-Coinfected Patients
- Author
-
Lo Re, III, Vincent, Teal, Valerie, Localio, A. Russell, Amorosa, Valerianna K., Kaplan, David E., and Gross, Robert
- Published
- 2013
- Full Text
- View/download PDF
16. The HCV Treatment Cascade by Prior Incarceration Status in Veterans With and Without HIV
- Author
-
Hawks, Laura, primary, Wang, Emily A., additional, Butt, Adeel A., additional, Crystal, Stephen, additional, McInnes, D. Keith, additional, Lo Re III, Vincent, additional, Cartwright, Emily J., additional, Puglisi, Lisa, additional, Haque, Lamia Y.K., additional, Lim, Joseph K., additional, Justice, Amy C., additional, and McGinnis, Kathleen A., additional
- Published
- 2021
- Full Text
- View/download PDF
17. Hepatocellular Cancer in the Absence of Viral Hepatitis: Implications for Prevention
- Author
-
Ilagan-Ying, Ysabel C., primary, Gordon, Kirsha S., additional, Tate, Janet, additional, Lim, Joseph K., additional, Lo Re III, Vincent, additional, Justice, Amy C., additional, and Taddei, Tamar H., additional
- Published
- 2021
- Full Text
- View/download PDF
18. 2896. Reduction in Liver-related Mortality Among HCV Infected Persons Is Driven by Attainment of SVR Independent of the Regimen Used: Results from the ERCHIVES Cohort
- Author
-
Butt, Adeel A, primary, Yan, Peng, additional, Aslam, Samia, additional, Lo Re III, Vincent, additional, and Shaikh, Obaid, additional
- Published
- 2019
- Full Text
- View/download PDF
19. The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection.
- Author
-
Saine, M. Elle, Szymczak, Julia E., Moore, Tyler M., Bamford, Laura P., Barg, Frances K., Forde, Kimberly A., Schnittker, Jason, Holmes, John H., Mitra, Nandita, and Lo Re III, Vincent
- Subjects
HEPATITIS C virus ,HIV infections ,DRUG abuse ,HEALTH & Nutrition Examination Survey ,SOCIAL stigma ,COMMON misconceptions - Abstract
Most patients with hepatitis C virus (HCV) infection perceive some degree of disease-related stigma. Misunderstandings about diseases may contribute to disease-related stigma. The objective of this study was to evaluate patient-level knowledge about HCV infection transmission and natural history and its association with HCV-related stigma among HCV-infected patients. We conducted a cross-sectional survey study among 265 patients with HCV in Philadelphia using the HCV Stigma Scale and the National Health and Nutrition Examination Survey (NHANES) Hepatitis C Follow-up Survey (2001–2008). The association between HCV knowledge and HCV-related stigma was evaluated via linear regression. Overall knowledge about HCV transmission and natural history was high, with >80% of participants answering ≥9 of 11 items correctly (median number of correct responses, 9 [82%]), HCV-related knowledge was similar between HIV/HCV-coinfected and HCV-monoinfected participants (p = 0.30). A higher level of HCV-related knowledge was associated with greater perceived HCV-related stigma (β, 2.34 ([95% CI, 0.51–4.17]; p = 0.013). Results were similar after adjusting for age, race, ethnicity, HIV status, education level, stage of HCV management, time since diagnosis, and history of injection drug use. In this study, increased HCV-related knowledge was associated with greater perceptions of HCV stigma. Clinicians may consider allotting time to address common misconceptions about HCV when educating patients about HCV infection, which may counterbalance the stigmatizing impact of greater HCV-related knowledge. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.
- Author
-
Gelfand, Joel M., Armstrong, April W., Bell, Stacie, Anesi, George L., Blauvelt, Andrew, Calabrese, Cassandra, Dommasch, Erica D., Feldman, Steven R., Gladman, Dafna, Kircik, Leon, Lebwohl, Mark, Lo Re III, Vincent, Martin, George, Merola, Joseph F., Scher, Jose U., Schwartzman, Sergio, Treat, James R., Van Voorhees, Abby S., Ellebrecht, Christoph T., and Fenner, Justine
- Abstract
Objective: To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic.Study Design: The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted.Results: The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus.Limitations: The evidence behind many guidance statements is variable in quality and/or quantity.Conclusions: These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
21. A semiparametric modeling approach using Bayesian Additive Regression Trees with an application to evaluate heterogeneous treatment effects
- Author
-
Zeldow, Bret, primary, Lo Re III, Vincent, additional, and Roy, Jason, additional
- Published
- 2019
- Full Text
- View/download PDF
22. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.
- Author
-
Gelfand, Joel M., Armstrong, April W., Bell, Stacie, Anesi, George L., Blauvelt, Andrew, Calabrese, Cassandra, Dommasch, Erica D., Feldman, Steve R., Gladman, Dafna, Kircik, Leon, Lebwohl, Mark, Lo Re III, Vincent, Martin, George, Merola, Joseph F., Scher, Jose U., Schwartzman, Sergio, Treat, James R., Van Voorhees, Abby S., Ellebrecht, Christoph T., and Fenner, Justine
- Abstract
Objective: To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic.Study Design: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted.Results: The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus.Limitations: The evidence behind many guidance statements is limited in quality.Conclusion: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
23. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study.
- Author
-
Rentsch, Christopher T., Kidwai-Khan, Farah, Tate, Janet P., Park, Lesley S., King, Joseph T., Skanderson, Melissa, Hauser, Ronald G., Schultze, Anna, Jarvis, Christopher I., Holodniy, Mark, Lo Re III, Vincent, Akgün, Kathleen M., Crothers, Kristina, Taddei, Tamar H., Freiberg, Matthew S., Justice, Amy C., King, Joseph T Jr, and Lo Re, Vincent 3rd
- Subjects
COVID-19 ,ELECTRONIC health records ,COHORT analysis ,SARS-CoV-2 ,ETHNICITY - Abstract
Background: There is growing concern that racial and ethnic minority communities around the world are experiencing a disproportionate burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19). We investigated racial and ethnic disparities in patterns of COVID-19 testing (i.e., who received testing and who tested positive) and subsequent mortality in the largest integrated healthcare system in the United States.Methods and Findings: This retrospective cohort study included 5,834,543 individuals receiving care in the US Department of Veterans Affairs; most (91%) were men, 74% were non-Hispanic White (White), 19% were non-Hispanic Black (Black), and 7% were Hispanic. We evaluated associations between race/ethnicity and receipt of COVID-19 testing, a positive test result, and 30-day mortality, with multivariable adjustment for a wide range of demographic and clinical characteristics including comorbid conditions, health behaviors, medication history, site of care, and urban versus rural residence. Between February 8 and July 22, 2020, 254,595 individuals were tested for COVID-19, of whom 16,317 tested positive and 1,057 died. Black individuals were more likely to be tested (rate per 1,000 individuals: 60.0, 95% CI 59.6-60.5) than Hispanic (52.7, 95% CI 52.1-53.4) and White individuals (38.6, 95% CI 38.4-38.7). While individuals from minority backgrounds were more likely to test positive (Black versus White: odds ratio [OR] 1.93, 95% CI 1.85-2.01, p < 0.001; Hispanic versus White: OR 1.84, 95% CI 1.74-1.94, p < 0.001), 30-day mortality did not differ by race/ethnicity (Black versus White: OR 0.97, 95% CI 0.80-1.17, p = 0.74; Hispanic versus White: OR 0.99, 95% CI 0.73-1.34, p = 0.94). The disparity between Black and White individuals in testing positive for COVID-19 was stronger in the Midwest (OR 2.66, 95% CI 2.41-2.95, p < 0.001) than the West (OR 1.24, 95% CI 1.11-1.39, p < 0.001). The disparity in testing positive for COVID-19 between Hispanic and White individuals was consistent across region, calendar time, and outbreak pattern. Study limitations include underrepresentation of women and a lack of detailed information on social determinants of health.Conclusions: In this nationwide study, we found that Black and Hispanic individuals are experiencing an excess burden of SARS-CoV-2 infection not entirely explained by underlying medical conditions or where they live or receive care. There is an urgent need to proactively tailor strategies to contain and prevent further outbreaks in racial and ethnic minority communities. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
24. FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C.
- Author
-
So-Armah, Kaku A., Lim, Joseph K., Lo Re III, Vincent, Tate, Janet P., Chang, Chung-Chou H., Butt, Adeel A., Gibert, Cynthia L., Rimland, David, Marconi, Vincent C., Goetz, Matthew Bidwell, Ramachandran, Vasan, Brittain, Evan, Long, Michelle, Nguyen, Kim-Lien, Rodriguez-Barradas, Maria C., Budoff, Matthew J., Tindle, Hilary A., Samet, Jeffrey H., Justice, Amy C., and Freiberg, Matthew S.
- Abstract
Background: Liver fibrosis, is independently associated with incident heart failure (HF). Investigating the association between liver fibrosis and type of HF, specifically HF with reduced ejection fraction (EF; HFrEF) or HF with preserved ejection fraction (HFpEF), may provide mechanistic insight into this association. We sought to determine the association between liver fibrosis score (FIB-4) and type of HF, and to assess whether HIV or hepatitis C status modified this association.Methods: We included patients alive on or after 4/1/2003 from the Veterans Aging Cohort Study. We followed patients without prevalent cardiovascular disease until their first HF event, death, last clinic visit, or 9/30/2015. We defined liver fibrosis as: likely advanced fibrosis (FIB-4 > 3.25), indeterminate (FIB-4 range 1.45-3.25), unlikely advanced fibrosis (FIB-4 < 1.45). Primary outcomes were HFrEF and HFpEF (defined using ICD-9 diagnoses for HF, and EF extracted from electronic medical records using natural language processing). Cox proportional hazards models were adjusted for potential confounders and used to estimate hazard ratios (HR).Results: Among 108,708 predominantly male (96%) participants mean age was 49 years. Likely advanced fibrosis was present in 4% at baseline and was associated with an increased risk of HFpEF [HR (95% confidence interval)] [1.70 (1.3-2.3)]; and non-significantly with HFrEF [1.20 (0.9-1.7)]. These associations were not modified by HIV or hepatitis C status.Conclusion: Likely advanced fibrosis was independently associated with incident HFpEF but not HFrEF. This suggests that risk factors and/or mechanisms for liver fibrosis may have greater overlap with those for HFpEF than HFrEF. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
25. Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection.
- Author
-
Saine, M. Elle, Moore, Tyler M., Szymczak, Julia E., Bamford, Laura P., Barg, Frances K., Mitra, Nandita, Schnittker, Jason, Holmes, John H., and Lo Re III, Vincent
- Subjects
HEPATITIS C virus ,COMPUTER adaptive testing ,ITEM response theory ,EXPLORATORY factor analysis ,SOCIAL stigma ,CRONBACH'S alpha ,HEPATITIS C - Abstract
Background: Stigma around hepatitis C virus (HCV) infection is an important and understudied barrier to HCV prevention, treatment, and elimination. To date, no validated instrument exists to measure patients' experiences of HCV stigma. This study aimed to revise the Berger (2001) HIV stigma scale and evaluate its psychometric properties among patients with HCV infection. Methods: The Berger HIV stigma scale was revised to ask about HCV and administered to patients with HCV (n = 270) in Philadelphia, Pennsylvania. Scale reliability was evaluated as internal consistency by calculating Cronbach's alpha. Exploratory factor analysis was performed to evaluate construct validity by comparing item clustering to the Berger HIV stigma scale subscales. Item response theory was employed to further evaluate individual items and to calibrate items for simulated computer adaptive testing sessions in order to identify potential shortened instruments. Results: The revised HCV Stigma Scale was found to have good reliability (α = 0.957). After excluding items for low loadings, the exploratory factor analysis indicated good construct validity with 85% of items loading on pre-defined factors. Analyses strongly suggested the predominance of an underlying unidimensional factor solution, which yielded a 33-item scale after items were removed for low loading and differential item functioning. Adaptive simulations indicated that the scale could be substantially shortened without detectable information loss. Conclusions: The 33-item HCV Stigma Scale showed sufficient reliability and construct validity. We also conducted computer adaptive testing simulations and identified shortened six- and three-item scale alternatives that performed comparably to the original 40-item scale. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed epatocellular Carcinoma.
- Author
-
Torgersen, Jessie, Taddei, Tamar H., Park, Lesley S., Carbonari, Dena M., Kallan, Michael J., Richards, Kisha Mitchell, Xuchen Zhang, Jhala, Darshana, Bräu, Norbert, Homer, Robert, D'Addeo, Kathryn, Mehta, Rajni, Skanderson, Melissa, Kidwai-Khan, Farah, Justice, Amy C., and Lo Re III, Vincent
- Abstract
Background: The incidence of hepatocellular carcinoma (HCC) is substantially higher among HIV-infected (HIV
+ ) than uninfected persons. It remains unclear if HCC in the setting of HIV infection is morphologically distinct or more aggressive. Methods: We evaluated differences in tumor pathology in a cohort of HIV+ and uninfected patients with microscopically confirmed HCC in the Veterans Aging Cohort Study from 2000 to 2015. We reviewed pathology reports and medical records to determine Barcelona Clinic Liver Cancer stage (BCLC), HCC treatment, and survival by HIV status. Multivariable Cox regression was used to determine the hazard ratio [HR; 95% confidence interval (CI)] of death associated with HIV infection after microscopic confirmation. Results: Among 873 patients with HCC (399 HIV+ ), 140 HIV+ and 178 uninfected persons underwent liver tissue sampling and had microscopically confirmed HCC. There were no differences in histologic features of the tumor between HIV+ and uninfected patients, including tumor differentiation (well differentiated, 19% vs. 28%, P = 0.16) and lymphovascular invasion (6% vs. 7%, P = 0.17) or presence of advanced hepatic fibrosis (40% vs. 39%, P = 0.90). There were no differences in BCLC stage (P = 0.06) or treatment (P = 0.29) by HIV status. After adjustment for risk factors, risk of death was higher among HIV-infected than uninfected patients (HR = 1.37; 95% CI, 1.02-1.85). Conclusions: We found no differences in HCC tumor characteristics or background hepatic parenchyma by HIV status, yet HIV was associated with poorer survival. Of note, pathology reports often omitted these characteristics. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
27. Trends in Treatment Uptake and Provider Specialty for Hepatitis C Virus (HCV) Infection in the Veterans Affairs Healthcare System: Results From the Electronically Retrieved Cohort of HCV-Infected Veterans (ERCHIVES)
- Author
-
Butt, Adeel A, primary, Yan, Peng, additional, Lo Re III, Vincent, additional, Shaikh, Obaid S, additional, and Ross, David B, additional
- Published
- 2018
- Full Text
- View/download PDF
28. Incidence, Microbiological Studies, and Factors Associated With Prosthetic Joint Infection After Total Knee Arthroplasty.
- Author
-
Weinstein, Erica J., Stephens-Shields, Alisa J., Newcomb, Craig W., Silibovsky, Randi, Nelson, Charles L., O'Donnell, Judith A., Glaser, Laurel J., Hsieh, Evelyn, Hanberg, Jennifer S., Tate, Janet P., Akgün, Kathleen M., King Jr, Joseph T., and Lo Re III, Vincent
- Published
- 2023
- Full Text
- View/download PDF
29. Disentangling the Postacute Sequelae of SARS-CoV-2: E Unibus Pluram (From One, Many).
- Author
-
Gross, Robert and Lo Re III, Vincent
- Subjects
- *
SARS-CoV-2 , *COUGH , *DISEASE complications , *POST-acute COVID-19 syndrome , *SARS-CoV-2 Omicron variant , *COVID-19 pandemic - Abstract
The study compared symptoms between those with and without SARS-CoV-2 infection to identify the symptoms most likely to characterize postacute sequelae. Editorial Early in the COVID-19 pandemic, patients and clinicians reported the persistence of initial symptoms and the onset of new symptoms after the acute phase of SARS-CoV-2 infection, collectively referred to as I postacute sequelae of SARS-CoV-2 infection i (PASC), or more colloquially called I long COVID i .[1] Persistent anosmia as well as debilitating physical symptoms, such as chronic cough, gastrointestinal symptoms, fatigue, malaise, myalgias, pain, and lack of clarity of thought ("brain fog"), with or without obvious organ dysfunction, were prominent ailments identified by numerous patients after acute COVID-19.[[1]] This phenomenon has been a major focus of research. However, before developing a case definition for PASC, it is important to consider whether these sequelae represent a single pathophysiologic process or rather multiple different conditions triggered by antecedent SARS-CoV-2 infection.[3] In addition, it is important to know whether they are direct sequelae of infection itself or are mediated by specific organ injury and dysfunction. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
30. Principal Agents of Bioterrorism: Recognition and Management
- Author
-
Lo Re, III, Vincent
- Subjects
Bioterrorism ,National security ,Plague ,Tularemia ,Public health ,Anthrax ,Smallpox - Abstract
The anthrax attacks in fall 2001 forced the public health and medical communities to face the very real possibility of future bioterrorist events. Bioterrorism is the use of biological agents [...]
- Published
- 2005
31. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy.
- Author
-
Cartwright, Emily J., Pierret, Chloe, Minassian, Caroline, Esserman, Denise A., Tate, Janet P., Goetz, Matthew B., Bhattacharya, Debika, Fiellin, David A., Justice, Amy C., Lo Re III, Vincent, and Rentsch, Christopher T.
- Published
- 2023
- Full Text
- View/download PDF
32. COVID-19 vs Influenza for Risk of Thrombotic Events in Hospitalized Patients—Reply.
- Author
-
Lo Re III, Vincent, Dutcher, Sarah K., and Cocoros, Noelle M.
- Subjects
- *
INFLUENZA , *HOSPITAL patients , *COVID-19 - Abstract
However, as shown in Table 1 of our article, the differences among the 2 COVID-19 cohorts and the influenza cohort were not large for the baseline variables. COVID-19 vs Influenza for Risk of Thrombotic Events in Hospitalized Patients - Reply We agree that there were differences in our study[1] in observed baseline characteristics between the cohorts of patients hospitalized with COVID-19 and influenza. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
33. Incidence, determinants and outcomes of pregnancy‐associated hepatitis B flares: A regional hospital‐based cohort study.
- Author
-
Kushner, Tatyana, Shaw, Pamela A., Kalra, Ankush, Magaldi, Lora, Monpara, Pooja, Bedi, Gurneet, Krok, Karen, Centkowski, Sierra, Dalldorf, Katherine, D'souza, Julia, Halegoua‐de Marzio, Dina, Goldberg, David S., Trooskin, Stacey, Levine, Lisa D., Srinivas, Sindhu K., Lewis, James D., Forde, Kimberly A., and Lo Re, Iii, Vincent
- Subjects
HEPATITIS B virus ,PREGNANCY complications ,HEPATITIS B treatment ,LOGISTIC regression analysis ,MATERNAL health ,PATIENTS - Abstract
Abstract: Background & Aims: There is limited knowledge about hepatitis B virus (HBV) flare among pregnant women. We evaluated the incidence, determinants and outcomes of HBV flare in a multicultural cohort of pregnant HBV‐infected women in the United States. Methods: We performed a retrospective cohort study of pregnant hepatitis B surface antigen‐positive women cared for at hospital‐based clinics of 4 medical centres in Southeastern Pennsylvania from 2006 to 2015. The main outcome was incident HBV flare (alanine aminotransferase [ALT] ≥2 times upper limit of normal) during pregnancy or within 6 months after delivery. Among patients with flare, we determined development of jaundice (total bilirubin ≥2.5 mg/dL) and hepatic decompensation. Multivariable logistic regression was used to estimate odds ratios (ORs) of HBV flare for risk factors of interest, including timing of flare (during pregnancy versus post‐delivery), nulliparity, younger age, HBV e antigen (HBeAg) status, and lack of anti‐HBV therapy. Results: Among 310 pregnant predominantly African HBV‐infected women with 388 pregnancies, the incidence of HBV flare was 14% (95% CI, 10‐18%) during pregnancy and 16% (95% CI, 11‐24%) post‐delivery. Jaundice developed in 12% and hepatic decompensation in 2%. Positive HBeAg was associated with HBV flare (OR, 2.55; 95% CI, 1.04‐6.20). HBV DNA was measured in 55% of patients, and only 50% were referred for HBV specialty care. Conclusions: Pregnancy‐associated hepatitis B flare occurred in 14% during pregnancy and 16% post‐delivery and rarely led to hepatic decompensation. Positive HBeAg was the main risk factor identified. Women did not have adequate HBV monitoring or follow‐up during pregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
34. Non antiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals.
- Author
-
Justice, Amy C., Gordon, Kirsha S., Skanderson, Melissa, Edelman, Eva Jennifer, Akgün, Kathleen M., Gibert, Cynthia L., Lo Re III, Vincent, Rimland, David, Womack, Julie A., Wyatt, Christina M., Tate, Janet P., Gordon, Kirsha, Edelman, E Jennifer, Akgun, Kathleen M, and Lo Re, Vincent 3rd
- Published
- 2018
- Full Text
- View/download PDF
35. Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.
- Author
-
Byrne, Dana D., Tate, Janet P., Forde, Kimberly A., Lim, Joseph K., Goetz, Matthew Bidwell, Rimland, David, Rodriguez-Barradas, Maria C., Butt, Adeel A., Gibert, Cynthia L., Brown, Sheldon T., Bedimo, Roger, Freiberg, Matthew S., Justice, Amy C., Kostman, Jay R., Roy, Jason A., and Lo Re III, Vincent
- Subjects
LIVER injuries ,AMINOTRANSFERASES ,CONFIDENCE intervals ,DEATH ,HEPATOTOXICOLOGY ,HIV infections ,LIVER diseases ,REGRESSION analysis ,CHRONIC hepatitis C ,STATINS (Cardiovascular agents) ,DISEASE risk factors - Abstract
Background. Patients with human immunodeficiency virus (HIV) and/or chronic hepatitis C virus (HCV) infection may be prescribed statins as treatment for metabolic/cardiovascular disease, but it remains unclear if the risk of acute liver injury (ALI) is increased for statin initiators compared to nonusers in groups classified by HIV/HCV status. Methods. We conducted a cohort study to compare rates of ALI in statin initiators vs nonusers among 7686 HIV/HCVcoinfected, 8155 HCV-monoinfected, 17 739 HIV-monoinfected, and 36 604 uninfected persons in the Veterans Aging Cohort Study (2000-2012). We determined development of (1) liver aminotransferases >200 U/L, (2) severe ALI (coagulopathy with hyperbilirubinemia), and (3) death, all within 18 months. Cox regression was used to determine propensity score-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of outcomes in statin initiators compared to nonusers across the groups. Results. Among HIV/HCV-coinfected patients, statin initiators had lower risks of aminotransferase levels >200 U/L (HR, 0.66 [95% CI, .53-.83]), severe ALI (HR, 0.23 [95% CI, .12-.46]), and death (HR, 0.36 [95% CI, .28-.46]) compared with statin nonusers. In the setting of chronic HCV alone, statin initiators had reduced risks of aminotransferase elevations (HR, 0.57 [95% CI, .45-.72]), severe ALI (HR, 0.15 [95% CI, .06-.37]), and death (HR, 0.42 [95% CI, .32-.54]) than nonusers. Among HIV-monoinfected patients, statin initiators had lower risks of aminotransferase increases (HR, 0.52 [95% CI, .40-.66]), severe ALI (HR, 0.26 [95% CI, .13-.55]), and death (HR, 0.19 [95% CI, .16-.23]) compared with nonusers. Results were similar among uninfected persons. Conclusions. Regardless of HIV and/or chronic HCV status, statin initiators had a lower risk of ALI and death within 18 months compared with statin nonusers. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
36. Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
- Author
-
Butt, Adeel A., Yanjie Ren, Lo Re III, Vincent, Taddei, Tamar H., and Kaplan, David E.
- Subjects
HEPATITIS C ,HEPATITIS C treatment ,HEPATITIS treatment ,HEPATITIS C diagnosis ,DRUG resistance in bacteria ,PATIENTS - Abstract
Background. Identifying hepatitis C virus (HCV)-positive persons at high risk of early complications can help prioritize treatment decisions. We conducted this study to compare Child-Turcotte-Pugh (CP), MELD, and FIB-4 scores for predicting clinical outcomes and to identify those at low risk of complications. Methods. Within electronically retrieved cohort of HCV-infected veterans, we identified HCV-positive persons and excluded those with human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), prevalent hepatic decompensation (HD), hepatocellular carcinoma (HCC), and those treated for HCV. We calculated incidence rates for HD, HCC, and all-cause mortality at 1, 3, and 5 years after HCV diagnosis. Using receiver operating characteristic (ROC) curves, we determined the optimal cut-off values for each score for these outcomes. Results. Among 21 116 persons evaluated, 89.7% were CP Class-A, 79.9% had MELD<9, and 43.4% had FIB-4<1.45. AUROC for HD at 1, 3, and 5 years was higher for FIB-4 (0.84-0.86) compared with MELD (0.70-0.76) (P < .001). AUROC for HCC at 1, 3, and 5 years was 0.81-0.82 for FIB-4 but 0.61-0.68 for CP and MELD scores. (P < .001) AUROC for all-cause mortality at 3 and 5 years was 0.65-0.68. The optimal cut-off scores to identify persons at low risk of complications were as follows: CP <5; MELD <8; FIB-4 <3 for HD and HCC, and <2 for all-cause mortality, below which <1.5% developed HD and HCC and ≤2.5% died at 3 years. Conclusions. FIB-4 score is a better predictor of HD and HCC in HCV-positive persons. A score of <3 is associated with a low risk of HD and HCC 1 and 3 years after HCV diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
37. Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.
- Author
-
Gowda, Charitha, Newcomb, Craig W., Qing Liu, Carbonari, Dena M., Lewis, James D., Forde, Kimberly A., Goldberg, David S., Reddy, K. Rajender, Roy, Jason A., Marks, Amy R., Schneider, Jennifer L., Kostman, Jay R., Tate, Janet P., Lim, Joseph K., Justice, Amy C., Goetz, Matthew Bidwell, Corley, Douglas A., and Lo Re III, Vincent
- Subjects
HIGHLY active antiretroviral therapy ,LIVER injury prevention ,VIRAL hepatitis ,THERAPEUTICS - Abstract
Background. The risk of hepatotoxicity with antiretroviral therapy (ART) remains unknown. We determined the comparative risk of acute liver injury (ALI) for antiretroviral drugs, classes, and regimens, by viral hepatitis status. Methods. We followed a cohort of 10 083 human immunodeficiency virus (HIV)-infected persons in Kaiser Permanente Northern California (n = 2099) from 2004 to 2010 and the Veterans Aging Cohort Study (n = 7984) from 2004 to 2012. Within the first year of ART, we determined occurrence of (1) liver aminotransferases >200 U/L and (2) severe ALI (coagulopathy with hyperbilirubinemia). We used Cox regression to determine hazard ratios (HRs) with 95% confidence intervals (CIs) of endpoints among initiators of nucleos(t)ide analogue combinations, antiretroviral classes, and ART regimens, all stratified by viral hepatitis status. Results. Liver aminotransferases >200 U/L developed in 206 (2%) persons and occurred more frequently among HIV/viral hepatitis-coinfected than HIV-monoinfected persons (116.1 vs 20.7 events/1000 person-years; P < .001). No evidence of differential risk was found between initiators of abacavir/lamivudine versus tenofovir/emtricitabine among coinfected (HR, 0.68; 95% CI, .29-1.57) or HIV-monoinfected (HR, 1.19; 95% CI, .47-2.97) groups. Coinfected patients had a higher risk of aminotransferases >200 U/L after initiation with a protease inhibitor than nonnucleoside reverse-transcriptase inhibitor (HR, 2.01; 95% CI, 1.36-2.96). Severe ALI (30 events; 0.3%) occurred more frequently in coinfected persons (15.9 vs 3.1 events/1000 person-years; P < .001) but was too uncommon to evaluate in adjusted analyses. Conclusions. Within the year after ART initiation, aminotransferase elevations were infrequently observed and rarely led to severe ALI. Protease inhibitor use was associated with a higher risk of aminotransferase elevations among viral hepatitis-coinfected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
38. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras.
- Author
-
Klein, Marina B., Althoff, Keri N., Yuezhou Jing, Lau, Bryan, Kitahata, Mari, Lo Re III, Vincent, Kirk, Gregory D., Hull, Mark, Kim, H. Nina, Sebastiani, Giada, Moodie, Erica E. M., Silverberg, Michael J., Sterling, Timothy R., Thorne, Jennifer E., Cescon, Angela, Napravnik, Sonia, Eron, Joe, Gill, M. John, Justice, Amy, and Peters, Marion G.
- Subjects
HIV infections ,HEPATITIS B virus ,HEPATITIS C virus ,ANTIRETROVIRAL agents ,LAMIVUDINE ,TENOFOVIR - Abstract
Background. Human immunodeficiency virus (HIV)-infected patients coinfected with hepatitis B (HBV) and C (HCV) viruses are at increased risk of end-stage liver disease (ESLD). Whether modern antiretroviral therapy has reduced ESLD risk is unknown. Methods. Twelve clinical cohorts in the United States and Canada participating in the North American AIDS Cohort Collaboration on Research and Design validated ESLD events from 1996 to 2010. ESLD incidence rates and rate ratios according to hepatitis status adjusted for age, sex, race, cohort, time-updated CD4 cell count and HIV RNAwere estimated in calendar periods corresponding to major changes in antiretroviral therapy: early (1996-2000), middle (2001-2005), and modern (2006-2010) eras. Results. Among 34 119 HIV-infected adults followed for 129 818 person-years, 380 incident ESLD outcomes occurred. ESLD incidence (per 1000 person-years) was highest in triply infected (11.57) followed by HBV- (8.72) and HCV- (6.10) coinfected vs 1.27 in HIV-monoinfected patients. Adjusted incidence rate ratios (95% confidence intervals) comparing the modern to the early antiretroviral era were 0.95 (.61-1.47) for HCV, 0.95 (.40-2.26) for HBV, and 1.52 (.46-5.02) for triply infected patients. Use of antiretrovirals dually activity against HBV increased over time. However, in the modern era, 35% of HBV-coinfected patients were not receiving tenofovir. There was little use of HCV therapy. Conclusions. Despite increasing use of antiretrovirals, no clear reduction in ESLD risk was observed over 15 years. Treatment with direct-acting antivirals for HCV and wider use of tenofovir-based regimens for HBV should be prioritized for coinfected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
39. Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection.
- Author
-
Gowda, Charitha, Brown, Todd T., Compher, Charlene, Forde, Kimberly A., Kostman, Jay, Shaw, Pamela A., Tien, Phyllis C., Lo Re III, Vincent, and Lo Re, Vincent 3rd
- Published
- 2016
- Full Text
- View/download PDF
40. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment.
- Author
-
Haque, Lamia Y., Fiellin, David A., Tate, Janet P., Esserman, Denise, Bhattacharya, Debika, Butt, Adeel A., Crystal, Stephen, Edelman, E. Jennifer, Gordon, Adam J., Lim, Joseph K., Tetrault, Jeanette M., Williams, Emily C., Bryant, Kendall, Cartwright, Emily J., Rentsch, Christopher T., Justice, Amy C., Lo Re III, Vincent, and McGinnis, Kathleen A.
- Published
- 2022
- Full Text
- View/download PDF
41. Is Moderate Alcohol Consumption Safe for Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women?
- Author
-
Lo Re III, Vincent
- Subjects
- *
DRINKING behavior , *ALCOHOL drinking , *HIV infections , *LIVER diseases , *PATIENT safety , *WOMEN'S health , *COMORBIDITY , *FIBROSIS , *DISEASE progression , *CHRONIC hepatitis C - Abstract
The article discusses whether moderate alcohol consumption is safe for human immunodeficiency virus or hepatitis C virus(HCV)–coinfected women. Topics include susceptibility of harm to chronic HCV patients with human immunodeficiency virus (HIV) coinfection, evaluation of effects of different levels of alcohol consumption on liver outcomes, and outcome regarding the rate of liver fibrosis progression.
- Published
- 2017
- Full Text
- View/download PDF
42. Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers
- Author
-
Butt, Adeel A., primary, Khan, Uzma A., additional, Shaikh, Obaid S., additional, McMahon, Deborah, additional, Dorey-Stein, Zachariah, additional, Tsevat, Joel, additional, and Lo Re III, Vincent, additional
- Published
- 2009
- Full Text
- View/download PDF
43. Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes
- Author
-
Lo Re III, Vincent, primary, Amorosa, Valerianna K., additional, Localio, A. Russell, additional, O’Flynn, Rose, additional, Teal, Valerie, additional, Dorey‐Stein, Zachariah, additional, Kostman, Jay R., additional, and Gross, Robert, additional
- Published
- 2009
- Full Text
- View/download PDF
44. Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein.
- Author
-
Lo Re III, Vincent, Lynn, Kenneth, Stumm, Emily R., Jin Long, Nezamzadeh, Melissa S., Baker, Joshua F., Hoofnagle, Andrew N., Kapalko, Angela J., Mounzer, Karam, Zemel, Babette S., Tebas, Pablo, Kostman, Jay R., and Leonard, Mary B.
- Subjects
- *
BONE abnormalities , *HIV infections , *HEPATITIS C virus , *BONE density , *BONE fractures , *DISEASES in women - Abstract
The VD4 region from the Chlamydia trachomatis major outer membrane protein contains important neutralizing B-cell epitopes of relevance for antibody-mediated protection against genital tract infection. We developed a multivalent vaccine construct based on VD4s and their surrounding constant segments from serovars D, E, and F. Adjuvanted with cationic liposomes, this construct promoted strong immune responses to serovar-specific epitopes, the conserved LNPTIAG epitope and neutralized serovars D, E, and F. Vaccinated mice were protected against challenge, with protection defined as reduced bacterial numbers in vagina and prevention of pathological changes in the upper genital tract. Adoptive transfer of serumand T-cell depletion experiments demonstrated a dominant role for antibodies and CD4+ T cells in the protective immune response. Integrating a multivalent VD4 construct into the sequence of the major outer membrane protein resulted in a protective and broadly neutralizing vaccine. Our findings emphasize the important role of antibodies in protection against Chlamydia trachomatis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
45. Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients.
- Author
-
Lo Re III, Vincent, Kallan, Michael J., Tate, Janet P., Lim, Joseph K., Bidwell Goetz, Matthew, Klein, Marina B., Rimland, David, Rodriguez-Barradas, Maria C., Butt, Adeel A., Gibert, Cynthia L., Brown, Sheldon T., Park, Lesley S., Dubrow, Robert, Reddy, K. Rajender, Kostman, Jay R., Justice, Amy C., and Localio, A. Russell
- Subjects
- *
LIVER diseases , *ANTIRETROVIRAL agents , *ASPARTATE aminotransferase - Abstract
Background. End-stage liver disease (ESLD) is an important cause of morbidity among human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients. Quantifying the risk of this outcome over time could help determine which coinfected patients should be targeted for risk factor modification and HCV treatment. We evaluated demographic, clinical, and laboratory variables to predict risk of ESLD in HIV/HCV-coinfected patients receiving antiretroviral therapy (ART). Methods. We conducted a retrospective cohort study among 6016 HIV/HCV-coinfected patients who received ART within the Veterans Health Administration between 1997 and 2010. The main outcome was incident ESLD, defined by hepatic decompensation, hepatocellular carcinoma, or liver-related death. Cox regression was used to develop prognostic models based on baseline demographic, clinical, and laboratory variables, including FIB-4 and aspartate aminotransferase-to-platelet ratio index, previously validated markers of hepatic fibrosis. Model performance was assessed by discrimination and decision curve analysis. Results. Among 6016 HIV/HCV patients, 532 (8.8%) developed ESLD over a median of 6.6 years. A model comprising FIB-4 and race had modest discrimination for ESLD (c-statistic, 0.73) and higher net benefit than alternative strategies of treating no or all coinfected patients at relevant risk thresholds. For FIB-4 >3.25, ESLD risk ranged from 7.9% at 1 year to 26.0% at 5 years among non-blacks and from 2.4% at 1 year to 14.0% at 5 years among blacks. Conclusions. Race and FIB-4 provided important predictive information on ESLD risk among HIV/HCV patients. Estimating risk of ESLD using these variables could help direct HCV treatment decisions among HIV/HCV-coinfected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
46. Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.
- Author
-
Saine, M. Elle, Carbonari, Dena M., Newcomb, Craig W., Nezamzadeh, Melissa S., Haynes, Kevin, Roy, Jason A., Cardillo, Serena, Hennessy, Sean, Holick, Crystal N., Esposito, Daina B., Gallagher, Arlene M., Bhullar, Harshvinder, Strom, Brian L., and Lo Re III, Vincent
- Subjects
HYPOGLYCEMIC agents ,TYPE 2 diabetes treatment ,ORAL drug administration ,DRUG efficacy ,PUBLIC health - Abstract
Background: The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4 (DPP-4) inhibitor oral anti-diabetic drugs (OADs) and identified factors associated with saxagliptin use. Methods: We conducted a cross-sectional study within the Clinical Practice Research Datalink (CPRD), The Health Improvement Network (THIN), US Medicare, and the HealthCore Integrated Research Database (HIRD
SM ) across the first 36 months of saxagliptin availability (29 months for US Medicare). Patients were included if they were: 1) =18 years old, 2) newly prescribed saxagliptin or a non-DPP-4 inhibitor OAD, and 3) enrolled in their respective database for 180 days. For each saxagliptin initiator, we randomly selected up to ten non-DPP-4 inhibitor OAD initiators matched on age, sex, and geographic region. Conditional logistic regression was used to identify determinants of saxagliptin use. Results: We identified 64,079 saxagliptin initiators (CPRD: 1,962; THIN: 2,084; US Medicare: 51,976; HIRDSM : 8,057) and 610,660 non-DPP-4 inhibitor OAD initiators (CPRD: 19,484; THIN: 19,936; US Medicare: 493,432; HIRDSM : 77,808). Across all four data sources, prior OAD use, hypertension, and hyperlipidemia were associated with saxagliptin use. Saxagliptin initiation was also associated with hemoglobin A1c results >8% within the UK data sources, and a greater number of hemoglobin A1c measurements in the US data sources. Conclusions: In these UK and US data sources, initiation of saxagliptin was associated with prior poor glycemic control, prior OAD use, and diagnoses of hypertension and hyperlipidemia. Trial registration: ClinicalTrials.gov identifiers NCT01086280, NCT01086293, NCT01086319, NCT01086306, and NCT01377935 [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
47. Prevalence and risk factors for patient-reported joint pain among patients with HIV/Hepatitis C coinfection, Hepatitis C monoinfection, and HIV monoinfection.
- Author
-
Ogdie, Alexis, Pang, Wyki Gina, Forde, Kimberly A., Samir, Bhangle D., Mulugeta, Lakeisha, Kyong-Mi Chang, Kaplan, David E., Amorosa, Valerianna K., Kostman, Jay R., Reddy, Rajender K., Schumacher, Ralph H., and Lo Re III, Vincent
- Subjects
JOINT diseases ,HIV-positive persons ,HEPATITIS C ,MIXED infections ,JOINT pain ,PATIENTS - Abstract
Background: To determine the prevalence of patient-reported joint pain among patients with human immunodeficiency virus (HIV)/chronic hepatitis C virus (HCV) coinfection, chronic HCV monoinfection, and HIV monoinfection followed in hepatology and infectious disease outpatient practices. Methods: Standardized interviews were performed among 79 HIV/HCV-coinfected, 93 HCV-monoinfected, and 30 HIV-monoinfected patients in a cross-sectional study within hepatology and infectious disease clinics at three centers. The Multi-Dimensional Health Assessment Questionnaire was used to ascertain joint pain and associated symptoms. Information on potential risk factors for joint pain was obtained during the interview and by chart review. Logistic regression was used to determine adjusted odds ratios (aORs) with 95% confidence intervals (CIs) of joint pain associated with risk factors of interest among chronic HCV-infected and HIV-infected patients. Results: Joint pain was more commonly reported in HCV-monoinfected than HIV/HCV-coinfected (71% versus 56%; p = 0.038) and HIV-monoinfected (71% versus 50%; p = 0.035) patients. A previous diagnosis of arthritis and current smoking were risk factors for joint pain among HCV-infected patients (arthritis: aOR, 4.25; 95% CI, 1.84-9.81; smoking: aOR, 5.02; 95% CI, 2.15-11.74) and HIV-infected (arthritis: aOR, 5.36; 95% CI, 2.01-14.25; smoking: aOR, 6.07; 95% CI, 2.30-16.00) patients. Conclusion: Patient-reported joint pain was prevalent among all three groups, but more common among chronic HCV-monoinfected than either HIV/HCV-coinfected or HIV-monoinfected patients. A prior diagnosis of arthritis and current smoking were risk factors for patient-reported joint pain among both HCV-infected and HIV-infected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
48. The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis.
- Author
-
Yehia, Baligh R., Schranz, Asher J., Umscheid, Craig A., and Lo Re III, Vincent
- Subjects
HEPATITIS C treatment ,SYSTEMATIC reviews ,META-analysis ,PUBLIC health ,RNA viruses ,VIROLOGY - Abstract
Background: Identifying gaps in care for people with chronic hepatitis C virus (HCV) infection is important to clinicians, public health officials, and federal agencies. The objective of this study was to systematically review the literature to provide estimates of the proportion of chronic HCV-infected persons in the United States (U.S.) completing each step along a proposed HCV treatment cascade: (1) infected with chronic HCV; (2) diagnosed and aware of their infection; (3) with access to outpatient care; (4) HCV RNA confirmed; (5) liver fibrosis staged by biopsy; (6) prescribed HCV treatment; and (7) achieved sustained virologic response (SVR). Methods: We searched MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews for articles published between January 2003 and July 2013. Two reviewers independently identified articles addressing each step in the cascade. Studies were excluded if they focused on specific populations, did not present original data, involved only a single site, were conducted outside of the U.S., or only included data collected prior to 2000. Results: 9,581 articles were identified, 117 were retrieved for full text review, and 10 were included. Overall, 3.5 million people were estimated to have chronic HCV in the U.S. Fifty percent (95% CI 43–57%) were diagnosed and aware of their infection, 43% (CI 40–47%) had access to outpatient care, 27% (CI 27–28%) had HCV RNA confirmed, 17% (CI 16–17%) underwent liver fibrosis staging, 16% (CI 15–16%) were prescribed treatment, and 9% (CI 9–10%) achieved SVR. Conclusions: Continued efforts are needed to improve HCV care in the U.S. The proposed HCV treatment cascade provides a framework for evaluating the delivery of HCV care over time and within subgroups, and will be useful in monitoring the impact of new screening efforts and advances in antiviral therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
49. Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus- Monoinfected Patients.
- Author
-
Lo Re III, Vincent, Kallan, Michael J., Tate, Janet P., Localio, A. Russell, Lim, Joseph K., Goetz, Matthew Bidwell, Klein, Marina B., Rimland, David, Rodriguez-Barradas, Maria C., Butt, Adeel A., Gibert, Cynthia L., Brown, Sheldont T., Park, Lesley, Dubrow, Robert, Reddy, K. Rajender, Kostman, Jay R., Strom, Brian L., and Justice, Amy C.
- Subjects
- *
HIV , *HEPATITIS C virus , *HEPATITIS C treatment , *HIV infections , *THERAPEUTICS , *ANTIRETROVIRAL agents , *DISEASE incidence , *HEALTH outcome assessment - Abstract
Background: The incidence and determinants of hepatic decompensation have been incompletely examined among patients coinfected with HIV and hepatitis C virus (HCV) in the antiretroviral therapy (ART) era, and few studies have compared outcome rates with those of patients with chronic HCV alone. Objective: To compare the incidence of hepatic decompensation between antiretroviral-treated patients co-infected with HIV and HCV and HCV-monoinfected patients and to evaluate factors associated with decompensation among co-infected patients receiving ART. Design: Retrospective cohort study. Setting: Veterans Health Administration. Patients: 4280 co-infected patients who initiated ART and 6079 HCV-monoinfected patients receiving care between 1997 and 2010. All patients had detectable HCV RNA and were HCV treatment–naive. Measurements: Incident hepatic decompensation, determined by diagnoses of ascites, spontaneous bacterial peritonitis, or esophageal variceal hemorrhage. Results: The incidence of hepatic decompensation was greater among co-infected than monoinfected patients (7.4% vs. 4.8% at 10 years; P 0.001). Compared with HCV-monoinfected patients, co-infected patients had a higher rate of hepatic decompensation (hazard ratio [HR] accounting for competing risks, 1.56 [95% CI, 1.31 to 1.86]). Co-infected patients who maintained HIV RNA levels less than 1000 copies/mL still had higher rates of decompensation than HCV-monoinfected patients (HR, 1.44 [CI, 1.05 to 1.99]). Baseline advanced hepatic fibrosis (FIB-4 score 3.25) (HR, 5.45 [CI, 3.79 to 7.84]), baseline hemoglobin level less than 100 g/L (HR, 2.24 [CI, 1.20 to 4.20]), diabetes mellitus (HR, 1.88 [CI, 1.38 to 2.56]), and nonblack race (HR, 2.12 [CI, 1.65 to 2.72]) were each associated with higher rates of decompensation among co-infected patients. Limitation: Observational study of predominantly male patients. Conclusion: Despite receiving ART, patients co-infected with HIV and HCV had higher rates of hepatic decompensation than HCV-monoinfected patients. Rates of decompensation were higher for co-infected patients with advanced liver fibrosis, severe anemia, diabetes, and nonblack race. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
50. FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patients.
- Author
-
Park, Lesley S., Tate, Janet P., Justice, Amy C., Lo Re III, Vincent, K. Lim, Joseph, Bräu, Norbert, Brown, Sheldon T., Butt, Adeel A., Gibert, Cynthia, Goetz, Matthew Bidwell, Rimland, David, Rodriguez-Barradas, Maria C., and Dubrow, Robert
- Abstract
The article discusses a research study on the association of the fibrosis marker (FIB-4) test index with hepatocellular carcinoma (HCC) among patients infected with human immunodeficiency virus (HIV). Study subjects include HIV-infected men from the Veterans Aging Cohort Study (VACS) with HCC diagnosis between 1996 and 2007 and compared intermediate FIB-4 score at 4.2 with high FIB-4 value of 13.0. Conclusions indicated that noninvasive FIB-4 tests can help in identifying high risks for HCC.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.